Veracyte, Inc. VCYT
Veracyte, Inc. (Nasdaq: VCYT) is an oncology diagnostics company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Decipher Prostate | Prostate cancer | unclear | Approved |
| Afirma | Thyroid cancer | unclear | Approved |
| Prosigna Breast Cancer Assay | Breast cancer | unclear | Approved |
| Decipher Bladder | Bladder cancer | unclear | Approved |
| TrueMRD for MIBC | Muscle-invasive bladder cancer | unclear | Approved |
| UroAmp platform | Urologic cancers (utDNA technology) | unclear | Pre-clinical |
Recent results and decisions
- Nov 4, 2026approval Veracyte secured Medicare reimbursement for its Prosigna Breast Risk of Recurrence test in the U.S. for eligible patients diagnosed with early-stage HR+ breast cancer.
Secured Medicare reimbursement for our Prosigna Breast Risk of Recurrence (ROR) test in the U.S. for eligible patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
- Legend Biotech Corp LEGN
- Indaptus Therapeutics, Inc. INDP
- SL Science Holding Ltd SLBT
- YD Bio Ltd YDES
- OnKure Therapeutics, Inc. OKUR
- Boundless Bio, Inc. BOLD
- NextCure, Inc. NXTC
- Akari Therapeutics Plc AKTX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.